Profound Medical Q1 2025 revenue $2.6M (+82% YoY); net loss $10.7M vs $6.6M

Profound Medical Corp.

2025-Q1 EPS reported $0.36 revenue$2,621,000

Revenue $2.6M, up 82% from $1.4M in Q1 2024; gross margin 71% vs 60%.
Net loss $10.7M ($0.36/share) vs $6.6M ($0.27/share) a year ago.
Operating expenses $13.0M, up from $8.7M on commercial expansion and R&D.
Cash $46.4M at March 31; 30,053,142 shares outstanding as of May 8.
Urology APC Level 7 codes effective 2025; TULSA-AI BPH module and TULSA+ planned H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.